Atlantic Pharmaceuticals, Inc. Announces Third Patent Issuance on SMART/Script™ Abuse Deterrent Drug Delivery System

Atlantic Pharmaceuticals, Inc. Announces Third Patent Issuance on SMART/Script™ Abuse Deterrent Drug Delivery System

ATLANTA, Aug. 21, 2013 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,507,001 that contains claims which cover Atlantic's SMART/Script™ abuse deterrent drug delivery system. SMART/Script™ is designed to prevent dose dumping of orally delivered prescription opioids and may sequester and reduce drug release of a pharmaceutical that has been subjected to a variety of physical methods of tampering.

(Logo: http://photos.prnewswire.com/prnh/20130821/PH67190LOGO )

SMART/Script™ has the potential to significantly impact prescription drug abuse by making a dosage form more difficult to manipulate and misuse via unintended routes of administration. "Based on its potential to retard or delay a drug's release rate when physically disrupted, we believe that a SMART/Script™ enabled dosage form could serve an important role in decreasing the epidemic prescription drug abuse problem currently observed in the U.S.," said Anthony Soscia, President of Atlantic Pharmaceuticals. "This patent issuance further strengthens the growing intellectual property portfolio we are building around SMART/Script™."

About SMART/Script™

SMART/Script™ (SMART, Simple, controllable, resistant, insoluble, physical trap) is designed to increase the difficulty of extracting a drug out of an oral dosage form and to deter the abuse of medications via known routes of abuse or misuse, including chewing, snorting, and injecting. Orally delivered prescription pharmaceuticals, such as narcotics, are frequently subjected to abuse and misuse via chewing and swallowing or crushing and either snorting or injecting the resultant powder in order to obtain a fast euphoria. A product formulated with SMART/Script™, however, resists extraction in water or alcohol and can be used with a broad range of opioids and non-opioids in immediate or extended release forms. SMART/Script™ is also unique among competitive technologies in that physical manipulation, such as chewing or crushing, may result in reducing the release rate of the drug as opposed to increasing it.

About Atlantic Pharmaceuticals, Inc.

Atlantic Pharmaceuticals is a specialty pharmaceutical company using its patented technology to produce novel therapeutics that resist attempts at tampering and may be useful to reduce abuse of certain prescription drugs. Based on the Company's proprietary technology, SMART/Script™, Atlantic is developing a pipeline of abuse-deterrent products that are nearing pivotal testing.

Visit atlanticpharma.com for more information.

Contact: Anthony Soscia
Email
404 994-5135

Read more news from Atlantic Pharmaceuticals

 

SOURCE Atlantic Pharmaceuticals, Inc.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.